S-Alpha Therapeutics develops digital therapeutics that combine information technology and biology, with several products in an R&D pipeline. The company is advancing SAT-001, its lead program for pediatric myopia, which is undergoing clinical evaluation at multiple sites in South Korea and is planned for further trials in the U.S. S-Alpha is also validating SAT-008, aimed at inducing immune-boosting effects, and is exploring business development models around evidence from clinical studies. The company uses its Series A proceeds to complete verification of SAT-008 and to support broader R&D across its pipeline. Founded in 2019 and based in Seoul, S-Alpha has positioned clinical validation as a near-term priority to demonstrate safety and efficacy. Financially, the company completed a $2.7M seed round in 2020 and closed an $8.7M Series A in 2021 to fund its development plans. S-Alpha Therapeutics is a Seoul, South Korea–based digital therapeutics company with platform technologies that enable digital devices to treat multiple disease areas. Its pipeline includes products in ophthalmology, neuropsychiatry, cancer, and immunology, with a lead product, SAT-001, aimed at treating eye disease. SAT-001 is in the process of regulatory submission to start clinical studies in Korea following MFDS guidance from June 2020, and the company completed a meeting with the US FDA in July 2020 to discuss development. S-Alpha is preparing to launch clinical studies in the United States and intends to use recent funding to execute those trials. The company is led by CEO Seung Eun Choi and Chief Medical Officer Dr. Myung Joon Kim. Financially, S-Alpha completed a seed round to support its clinical development activities.

Total raised

$11M

Funding rounds

2

Latest round

Series A

Latest activity

Aug 2021